Zachary Aldridge, APRN
Psychiatric/Mental Health · Warren, OHNPI 1538712922
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 83.7% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $26,759, more than ten times the $2,124 reported in 2021. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 437 payments — averaging $99.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$36K
- Biogen$1K
- Lundbeck LLC$898
- Otsuka America Pharmaceutical, Inc.$824
- AbbVie$761
- Alkermes, Inc.$656
- plus $3K from 17 others
What the payments were for
- Consulting fees$12,98830%
- Speaking & faculty fees$18,56543%
- Travel & lodging$3,9379%
- Food & beverage$8,04718%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 87 | $36,480 |
| Biogen | 2 | $1,215 |
| Lundbeck LLC | 59 | $898 |
| Otsuka America Pharmaceutical, Inc. | 50 | $824 |
| AbbVie | 52 | $761 |
| Alkermes, Inc. | 25 | $656 |
| Teva Pharmaceuticals USA, Inc. | 59 | $654 |
| E.r. Squibb & Sons, L.L.C. | 14 | $447 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $416 |
| Axsome Therapeutics, Inc. | 8 | $175 |
| Johnson & Johnson | 8 | $168 |
| Vanda Pharmaceuticals Inc. | 8 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $131 |
| Sunovion Pharmaceuticals Inc. | 2 | $110 |
| Corium, LLC | 6 | $107 |
| Noven Therapeutics, LLC | 6 | $95 |
| Almatica Pharma LLC | 6 | $90 |
| Supernus Pharmaceuticals, Inc. | 4 | $66 |
| Tris Pharma Inc | 3 | $53 |
| Indivior Inc. | 2 | $39 |
| Adlon Therapeutics L.p. | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,583 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 65 | $480,864 |
| IngrezzaValbenazine Tosylate | 112 | $457,575 |
| AustedoDeutetrabenazine | 75 | $223,247 |
| Invega SustennaPaliperidone Palmitate | 71 | $218,037 |
| RexultiBrexpiprazole | 136 | $193,306 |
| Invega TrinzaPaliperidone Palmitate | 20 | $150,250 |
| VraylarCariprazine Hcl | 103 | $140,342 |
| AristadaAripiprazole Lauroxil | 15 | $45,422 |
| CaplytaLumateperone Tosylate | 20 | $34,149 |
| Paliperidone ErPaliperidone | 199 | $27,390 |
| Clozapine | 198 | $22,364 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $16,774 |
| TrintellixVortioxetine Hydrobromide | 31 | $14,187 |
| Lurasidone Hcl | 101 | $13,753 |
| VyvanseLisdexamfetamine Dimesylate | 35 | $13,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $654 | $704,110140 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $36,480 | $457,575112 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $168 | $377,801103 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $824 | $193,306136 claims |
| AbbVieVraylar, Viibryd | $761 | $144,465114 claims |
| Alkermes, Inc.Aristada | $656 | $45,42215 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $416 | $34,14920 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $131 | $27,63566 claims |
| Axsome Therapeutics, Inc.Auvelity | $175 | $16,77421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Warren
- Mary HallWarren$195K
- Rachelle SchneiterWarren$15K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.